-Dacomitinib (Vizimpro, PF-00299804, Figure 4f [139]), another second-generation EGFR inhibitor, was approved by the FDA in 2018 as the first-line treatment of patients with metastatic NSCLC with EGFR-activating mutations (exon 19 deletion or exon 21 substitution L858R) (Table 1) [140]. Here, EGFR is linked to non-small cell lung carcinoma.